Initial Statement of Beneficial Ownership (3)
10 November 2022 - 09:06AM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP
OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
1. Name
and Address of Reporting Person * Welsh
Amy |
2. Date of Event Requiring Statement
(MM/DD/YYYY)
11/1/2022
|
3. Issuer Name and Ticker or Trading
Symbol AGILE THERAPEUTICS INC [AGRX] |
(Last)
(First)
(Middle)
500 COLLEGE ROAD EAST, SUITE 310 |
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)_____
Director _____
10% Owner
___X___ Officer (give title
below) _____
Other (specify below)
Chief Commercial Officer / |
(Street)
PRINCETON,, NJ 08540
(City)
(State)
(Zip)
|
5. If Amendment, Date Original
Filed(MM/DD/YYYY)
|
6. Individual or Joint/Group
Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially
Owned
|
1.Title of Security
(Instr. 4) |
2. Amount of Securities Beneficially Owned
(Instr. 4) |
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) |
4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 4) |
2. Date Exercisable and Expiration Date
(MM/DD/YYYY) |
3. Title and Amount of Securities Underlying
Derivative Security
(Instr. 4) |
4. Conversion or Exercise Price of Derivative
Security |
5. Ownership Form of Derivative Security: Direct (D)
or Indirect (I)
(Instr. 5) |
6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
Employee Stock Option (Right to Buy) |
(1) |
4/27/2030 |
Common Stock |
1500 |
$95.60 |
D |
|
Employee Stock Option (Right to Buy) |
(2) |
1/27/2031 |
Common Stock |
1000 |
$112.80 |
D |
|
Employee Stock Option (Right to Buy) |
(3) |
1/19/2032 |
Common Stock |
1000 |
$13.68 |
D |
|
Explanation of
Responses: |
(1) |
This option was granted on
April 27, 2020. 25% of the shares subject to the stock option
vested on April 27, 2021, and the remaining shares vest in 36 equal
monthly installments over the following three years, such that the
option will be fully vested by April 27, 2024. |
(2) |
This option was granted on
January 27, 2021. 25% of the shares subject to the stock option
vested on January 27, 2022, and the remaining shares vest in 36
monthly installments over the following three years, such that the
option will be fully vested by January 27, 2025. |
(3) |
This option was granted on
January 19, 2022. 25% of the shares subject to the stock option
vest on January 19, 2023, and the remaining shares vest in 36 equal
monthly installments over the following three years, such that the
option will be fully vested by January 19, 2026. |
Remarks:
Exhibit List 24.1 - Power of Attorney |
Reporting
Owners
|
Reporting Owner Name / Address |
Relationships
|
Director |
10% Owner |
Officer |
Other |
Welsh Amy
500 COLLEGE ROAD EAST, SUITE 310
PRINCETON,, NJ 08540 |
|
|
Chief Commercial Officer |
|
Signatures
|
/s/ Geoffrey P. Gilmore
Attorney-in-Fact |
|
11/9/2022 |
**Signature
of Reporting Person |
Date |
Reminder: Report on a separate line for each class
of securities beneficially owned directly or
indirectly. |
* |
If the form is filed by more than one
reporting person, see Instruction 5(b)(v). |
** |
Intentional misstatements or omissions
of facts constitute Federal Criminal Violations. See 18
U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: |
File three copies of this Form, one of
which must be manually signed. If space is insufficient, see
Instruction 6 for procedure. |
Persons who respond to the collection of information
contained in this form are not required to respond unless the form
displays a currently valid OMB control number. |
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From May 2023 to Jun 2023
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Jun 2022 to Jun 2023